Rhumbline Advisers Allovir, Inc. Transaction History

Rhumbline Advisers

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$0.72 - $0.82 $36,363 - $41,414	-50,505 Reduced 73.2%	18,494 $13,000
Q1 2024 May 09, 2024	BUY	$0.64 - $0.78 $3,443 - $4,197	5,381 Added 8.46%	68,999 $52,000
Q4 2023 Feb 08, 2024	SELL	$0.68 - $2.39 $10,843 - $38,110	-15,946 Reduced 20.04%	63,618 $43,000
Q3 2023 Nov 09, 2023	BUY	$2.15 - $3.64 $33,722 - $57,093	15,685 Added 24.55%	79,564 $171,000
Q2 2023 Aug 08, 2023	BUY	$3.17 - $5.82 $49,065 - $90,081	15,478 Added 31.98%	63,879 $217,000
Q1 2023 May 11, 2023	SELL	$3.94 - $7.05 $4,747 - $8,495	-1,205 Reduced 2.43%	48,401 $191,000
Q4 2022 Feb 14, 2023	BUY	$4.7 - $9.98 $8,958 - $19,021	1,906 Added 4.0%	49,606 $254,000
Q3 2022 Nov 10, 2022	BUY	$4.13 - $8.79 $17,643 - $37,550	4,272 Added 9.84%	47,700 $376,000
Q2 2022 Aug 11, 2022	BUY	$3.26 - $7.06 $47,977 - $103,902	14,717 Added 51.26%	43,428 $169,000
Q1 2022 May 12, 2022	BUY	$6.75 - $13.52 $6,945 - $13,912	1,029 Added 3.72%	28,711 $194,000
Q4 2021 Feb 10, 2022	SELL	$12.94 - $25.99 $6,806 - $13,670	-526 Reduced 1.86%	27,682 $358,000
Q3 2021 Nov 12, 2021	BUY	$16.97 - $25.06 $22,247 - $32,853	1,311 Added 4.87%	28,208 $707,000
Q2 2021 Aug 05, 2021	SELL	$19.44 - $25.06 $38,199 - $49,242	-1,965 Reduced 6.81%	26,897 $531,000
Q1 2021 May 06, 2021	BUY	$20.81 - $45.5 $186,457 - $407,680	8,960 Added 45.02%	28,862 $675,000
Q4 2020 Feb 10, 2021	BUY	$23.94 - $46.81 $92,384 - $180,639	3,859 Added 24.05%	19,902 $765,000
Q3 2020 Nov 12, 2020	BUY	$21.05 - $42.7 $337,705 - $685,036	16,043 New	16,043 $441,000

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $51.2M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.